DOCSLIB.ORG

KOL Event & Corporate Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KOL Event & Corporate Update KOL Event & Corporate Update April 6, 2017 NASDAQ: VBLT Agenda Opening remarks Dr. Ramy Ibrahim, MD – Parker institute for Cancer Immunotherapy New Targets and Immuno‐therapeutic Approaches in Oncology Prof. Dror Harats, MD – CEO, VBL Therapeutics VBL’s Novel Approach to Immune‐Oncology 2 Use of checkpoint modulators in Advanced malignancies Ramy Ibrahim, MD Head of Clinical Development Disclosures Paid consultant for Arcus therapeutics Honorarium from PER History and evolution of immunotherapy Immunotherapy Delivers In 2013, Science selected cancer immunotherapy as its Breakthrough of the Year. In 2014, the Wall Street Journal showcased cancer patients who were treated with immunotherapies and survived years beyond their initial prognosis. Ambitious goal with immunotherapy Traditional Therapies Immunotherapy 100% 100% Long Term Benefit Combinations of Traditional Immunotherapy Cancer Therapies Alive Alive Immunotherapy % of Treated %Patients of Treated % of Treated %Patients of Treated Traditional Therapies 0% 0% Time Time Patients ultimately succumb to their disease 2011: Immunotherapy delivered Long term benefit: Only 1in every 5 treated patients Mechanism of Action is simple… MEMORY cell Cancer cell It is more complicated…many pathways Some activate , others inhibit but many remain to be unknown Unleashing Immunotherapy’s Potential Multi disciplinary Genomics Immunomics Proteomics Microbiome Clinical Outcomes Data Science >1,250+ companies Biology >3,000 IO trials Oncology 100’s of research institutions Physics + Chemistry 100’s of disease and immune pathways Is it The Matrix 2.0? Unlimited Number of Potential Combinations And… That’s Actually What’s Happening in the Clinic SCLC nsqNSCLC Colorectal Phase I Pembro+chemoradiaton Pembro+ PD-1 Pathway Atezol CVA21 durva+ Pembro+INCB039110 + erlotinib AMP-224 Pancreas NSCLC Durva+Treme+HF radiation Treme++INCB050465 Pembro+XBRT +SBRT Pembro+CM-24 Avelumab +Crizotinib Durva+ carboplatin + Nivo + Pembro+azacitidine+ Phase II Durva+AZD9291 Ramucirumab Pembroetoposide FP008 Durva+ Romidepsin Pembro+RESOLYN Atezo Nivo+ Nab-Paclitaxel + Gemcitabine Atezo+ sterotactic radiation Nivo+Ipi+ACY 241 +taxol Ramucirumab Combo + bevacizumabdurva+ Pembro+ Durva+Treme+HF radiation NivoCheckmate012 Pembro+ Pembro+INCB039110 +chemo azacitidine Nivo+FP008 Nivo+Nab-Paclitaxel Nivo+ Ipi+nivo MargetuximabAM0010 Durva+treme+radiation +INCB050465 durva+ Hepatic Atezo+radiation + Gemcitabine Decitabine/Tetrahydrouridine i Nivo+FP008 Treme+ Atezo Phase III Avelumab +AZD5069 Pembro+Carboplatin/Nab-Paclitaxel Nivo+Ipi durva+ Pembro+AM0010PDR001 Nivo+CB-839 Folfox+ + bevacizumab Pembro+CM-24 Durva+Selected Small Molecules Treme+ +IMCS110 Atezo+INCB024360 +chemo Nivo+Ipi+TAK-580 Nivo+BMS-936558 radiation bevacizumab Pembro+afatinib Nivo+INC280 Nivo+HBI-8000 Pembro+Cyclophosphamide+GVAX+SBRT PDR001 TAK-202 Nivo+ class I peptides Pembro Pembro Nivolo+Vigil +INC280 Vedolizumab + ISA 51 VG+ipi Nivo+ALT803 (Keynote-021) Pembro+CDX-1401 + Azacitidine Nivo+GVAX+CRS-207 Nivo+Ipi+ Nivo+dasatinib Pembro Durva+Ramucirumab Pembro+ Pembro+crizotonib Nivo+crizotonib +PolyICLC Nivo+GVAX laser beam Pembro after + ACT Pembro+ Atezo Melanoma Peg-IFNa-2b Pembro+Vorinostat Pembro+CDX-1401 Nivo Pembro+ radoitherapy Frontline chemo Atezo Neoadjuvant Chemoradiation + bevacizumab Atezo + Vemurafenib Pembro +PolyICLC +Ipi +chemo Indoximod + carbo+ Pembro Nivo+chemo HNC Nivo+Trametinib+Dabrafenib Nivo+Ipi+ +INCB024360 Durva+ nab-Atezo+Cobimetinib Pembro+Ipi Durva+Bavituximab etoposide + cetuximab Pembro+Vemurafenib Nivo+ACT+ radiation Nivo+desatinib paclitaxel Pembro+INCB039110+ Pembro+imatinib Nivo+Ceritinib Nivo+ablation Nivo+erlotonib durva+treme Urelumab Pembro+Trametinib+Dabrafenib Nivo+BMS-986016 Pembro + gemcitabine INCB050465 Pembro+CDX-1401 Nivo+galunisertib PDR001 Pembro+IL-2+ ACT Pembro+ Pembro+GMCSF +PolyICLC + AMG 820 Nivo+FP008 +IMCS110 Pembro+ Nivo+ Nivo+HBI-8000 Atezo+SOCPembro+bevacizumab chemo ACP-196 Durva+Treme Pembro+ Cavatak Nivo + ipi + XRT Atezo Pidilizumab Nivo+Galunisertib Pembro+ doxcetaxel Durva+ADXS11-001 +HF radiation Indoximod Sargromstim Pembro+PV-10 Nivo+ Nivo+Ipi Nivo+XRT+ carbo+ +Gemcitabine Nivo+ipi Pembro+ adjuvant cisplatin + radiation Nivo+FP008 durva+treme Pembro+AM0010 Indoximod +chemo etoposide Durva+Trametnib+Debrafenib Nivo+ INCB24360 Nivo+Sunitinib durva+treme Pembro+chemoradiationPembro+chemotherapy durva+treme+ paclitaxel + carboplatin Pembro+ LV305 Pembro+IL-2 Nivo+ipi+LGX818MEK162 avelumab+doxcetaxl Pembro+ radiation Nivo+HAM Pembro+bevacizumab Atezo+Cobimetinib Pembro +GR-MD-02 Pembro+pIL12 durva+treme+Poly(ICLC) Cervical Pembro + HAM Durva+Treme+IMCgp100 Pembro+ Nivo+surg+chemo Nivo+Ipi epacadostat Atezo+chemo+bevacizumab Nivo+FP008 Durva+ADXS11-001 Nivo+CB-839 Ipi+IMO-2125 Nivo+ Ipili After Nivo progression Nivo+chemo Durva+Treme GBM + Trametinib + Dabrafenib Durva+Avastin Sarcoma Atezo+chemo +XRT durva+treme+Poly(ICLC) Durva+treme Nivo+DC vaccines Nivo+ Ipi Nivo+Ipi Nivo+Ipi Pembro+ BevacizumabDurva+Avastin Atezo+CMB305 Checkmate-401 Nivo+WT1vaccine Pembro+Axitinib Nivo+ Radiation + Urelumab+BMS-986016 Pembro+AM0010 Pembro+chemo Pembro Avelumab+carbo/tax Nivolumab Nivo+Ipi Nivo+Radiation Temozolomide durva+paclitaxel + Ipilimumab Nivo+Temozolomide durva+treme+ +carboplatin Durva+Motolomid+doxyrubicin +ACP-196 Avelumab +Doxyrubicin Nivo+Urelumab paclitaxel + carboplatin Durva+ Olaparib Atezo+chemo Pembro+chemotherapy durva+ Atezo+bevacizumab+ Pembro+ Doxyrubicin Nivo+ durva+Lenalidomide+Rituximab Ovarian Ipi durva+treme+Poly(ICLC) azacitidine aspirin Atezo+entinostat and/or anti-estrogen therapyAtezo+ Nab-Paclitaxel Nivo+Elotuzumab Pembro+CTL019 Pembro+CM-24 durva+Trastuzumab durva+ Nivo+brentuximab vedotin durva+treme+gemcitabine+ carboplatin Pembro+nabpax Atezo Pomalidamide Pembro+carbo Durva+treme Pembro+ Bendamustine+ Atezo durva+treme+ Pembro+cyclo Pembro+CDX-1401 + gem/carbo Dex Pembro durva+bev +gemcitibine Nivo+varilumab lenvatinib Pembro+Ublituximab Rituximab + Obinutuzumab+Lenalidomide nab-paclitaxel + carboplatin +PolyICLC + ACP-196 Atezo Nivo+ Pembro+eribulin Durva+Taxane-anthracycline Chemo durva+ +TGR-1202 Pembro durva+Vigil durva+INCB024360 Atezo+ Durva+MEDI6469 + Obinutuzumab+ Nab-Paclitaxel mesylate durva+treme+Poly(ICLC) treme+Poly(ICLC) Nivo+ + AFM13 Pembro+INCB054828 Pembro+Cetuximab Bevacizumab Nivo+Ipi durva+ Polatuzumab Vedotin durva+JCAR014 +Gemcitabine Pembro+Tamoxifen Nivo+BMS-986179 Durva+MEDI6469 LAG3 Pembro+ +post Bendamustine+ BreastPembro+AM0010 Pembro+Stereotactic Ablation Nivo+BMS-986156 Durva+AZACITIDINE Pembro+INCB039110 TSR-022+TSR-042 Durva+ Bevacizumab ASCT Rituximab PDR001+GWN323 Lymphomas durva+PDR001 Pembro+GSK3174998 PDR001 Durva+ Nivo+5-azacytidine +INCB050465 Mocetinostat Nivo+XRT Pidilizumab + Lenalidomide azacitidine+IMCS110 Pembro+Hypofractionated Radiotherapy + LAG25 Treme Pembro+ Nivo+cyclo+XRT Pembro+selexnor +SOC pTVG-HP Plasmid Nivo+Imbrutinib Pidilizumab +DC vaccine Lirilumab+ Nivolumab+5-azacytidine Pembro+IPI-549 PDR001 Pembro Avelumab + PF-05082566 DNA Vaccine Pembro+MK-4166 Atezo+MTIG7192A + MGB453 Pembro (Keynote-29) durva+ibrutinib Atezol+ lenalidomide Pembro+GSK3359609 Atezo+RO7009789 Durva+ Pembro+Pomalidomide +CDX-1401 Atezo+Azacitidine Pembro+PF-05082566 BGB-A317+BGB-290 Nivo+HBI-8000 Durva+LY3022855 Pembro+Birinapant +PolyICLC treme Durva+Pomalamide BGB-A317+BGB-317 nivo+Mogamulizumab Pidilizumab + Nivo+CB-839 + Dexamethasone+Dara Durva+treme+Mogamulizumab Pembro+Ziv-aflibercept durva+ Pembro+ Idelalisib Nivo Provenge+ Durva+Pomalamide Nivo+ IFNg Pembro treme+ Nivo+Dasatinib +vaccine+ PDR001 Cyclo + Dexamethasone Durva+ Nivo+lirilumab Durva+LY2510924 +ACP-196 durva+ Nivo+Urelumab Pembro+Ibrutinib NYESO1 ACT+GWN323 Nivo Pembro+ADXS31-142 treme+ Pembro+TILs AZD1775 Nivo+ABBV-399 Pembro Pembro+vaccine Nivo+ Pembro+dinaciclib + anti-LAG3 Poly(ICLC) Pembro+ Atezo+emactuzumab +EphB durva+treme Ipi or lirilumab Durva+ Pidilizumab + DC vaccine Pembro+INCB054828 Lenvatinib Atezo+IFNalpha 4-HSA +Poly(ICLC) Nivo MEDI0680 Nivo+desatnib Atezo+RO6895882 Avelumab +BMS-986205 Durva+ Nivo+PT2385 pembro Advanced Atezo+ipi AZD4547 +Pembro+Axitinib Axitinib +post Atezo+RO6958688 durva+ Hematological Atezo+GDC-0919 Atezo Nivo Checkmate016 ASCT treme+ Malignancies Durva+MEDI9447 + BCG Durva+IPH2201 Pembro+ Atezo Pembro+AM0010 CRI Venture Fund Durva+AZD4635 INCB054828 + R-223-D Pembro+INCB039110+INCB050465 pembro Pembro Merkel + BCG +CM-24 Landscape Pembro+AM0010 Bladder Prostate Renal This will happen because of “data overload” 2014: The year of phase 1 and 2 clinical trials Tsunami 250 200 150 trials of Phase I Phase II 100 Number Phase III 50 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Year There are 97 immune modulators in clinical development. • 38 monotherapy only • 59 in combination in ~ 1100 trials As of March 2017 : ~130,000 patients as expected to be enrolled in ongoing clinical trials Source: Beacon Data base Wide Range of Agents or Modalities Being Combined with 1st Generation IO Agents: PD1, PDL1 and CTLA4 800 700 600 Adoptive Transfer (incl. CAR‐T) Antibody Drug Conjugate 500 HDAC Inhibitor Cytokine/Chemokine trials of 400 Surgery Immunomodulator Number Vaccine 300 Radiotherapy ICM Doublet 200 Kinase Inhibitor Chemotherapy 100 0 PD‐1PD‐L1 CTLA‐4 ICM target Data: March 2017. Same Trend is Emerging with Next Wave of IO Beyond PD1, PDL1 and CTLA4 40 35 30 Adoptive Transfer (incl. CAR‐T) Antibody Drug Conjugate 25 HDAC Inhibitor Cytokine/Chemokine trials of 20 Surgery Immunomodulator Number Vaccine 15 Radiotherapy
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • The Pipeline Report 2016 Pipeline 2014 Autoimmune
    THE PIPELINE REPORT 2016 PIPELINE 2014 AUTOIMMUNE PRODUCTS GENERATING BUZZ OTHER KEY PRODUCTS IN THE PIPELINE BIG-TIME Baricitinib Eli Lilly/Incyte Indication: RA (Ph.III) Romosozumab Amgen/UCB Sirukumab Janssen Biotech RA What the clinical trials found: The daily oral demonstrated superiority Osteoporosis (Ph.III) (Ph.III) compared to placebo after 12 weeks based on ACR20 response (Ph. Avatrombopag Astellas Pharma Anifrolumab Medarex/Med­ III RA-BEAM). The agent also proved superior to adalimumab on ITP/thrombocytopenia (Ph.III) Immune Systemic lupus erythema- tosus (Ph.III) key secondary objectives of ACR20 response and improvement in Elobixibat AstraZeneca CIC and DAS28-hsCRP score. A few occasional AEs were reported. IBS-C (Ph.III) Odanacatib Merck Osteoporosis (Ph.III) Credit Suisse Success Probability and inThought Comment: 70%. Lesinurad AstraZeneca Gout (Ph. III) Tildrakizumab Merck Psoriasis The JAK inhibitor appears to have similar efficacy and safety to (Ph.III) Pfizer’s Xeljanz. It was supposed to have a once daily vs. Xeljanz’s Alicaforsen Atlantic Healthcare Pouchitis/ulcerative colitis (Ph.III) Siponimod Novartis MS (Ph.III) twice daily advantage, but Xeljanz’s once daily formulation will likely be approved soon. It’ll be interesting to see if Lilly/Incyte Rituximab biosimilar Boehringer Infliximab biosimilar Pfizer RA Ingelheim RA (Ph.III) (Ph.III) can do something with patient access and price to improve upon Mongersen Celgene/Nogra RHB 104 RedHill Biopharma the poor performance of Xeljanz and expand the JAK inhibitor Pharma Crohn’s disease (Ph.III) Crohn’s disease (Ph.III) market. Expected launch: 2016 (Source: Credit Suisse) Etanercept biosimilar Coherus Sarilumad Regeneron RA (Ph.III) Credit Suisse forecast: $1.09 billion in global annual sales by 2020 Biosciences/Daiichi Sankyo/ Etrolizumab Roche Ulcerative A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom.
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
    cells Review Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses Clément Anfray 1, Aldo Ummarino 2 , Fernando Torres Andón 1,3 and Paola Allavena 1,* 1 IRCCS Istituto Clinico Humanitas, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy; [email protected] (C.A.); [email protected] (F.T.A.) 2 Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy; [email protected] 3 Center for Research in Molecular Medicine & Chronic Diseases (CIMUS), Universidade, de Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain * Correspondence: [email protected] Received: 4 December 2019; Accepted: 20 December 2019; Published: 23 December 2019 Abstract: Established evidence demonstrates that tumor-infiltrating myeloid cells promote rather than stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at tumor sites, and here they support cancer proliferation and distant spreading, as well as contribute to an immune-suppressive milieu. Their pro-tumor activities hamper the response of cancer patients to conventional therapies, such as chemotherapy or radiotherapy, and also to immunotherapies based on checkpoint inhibition. Active research frontlines of the last years have investigated novel therapeutic strategies aimed at depleting TAMs and/or at reprogramming their tumor-promoting effects, with the goal of re-establishing a favorable immunological anti-tumor response within the tumor tissue. In recent years, numerous clinical trials have included pharmacological strategies to target TAMs alone or in combination with other therapies. This review summarizes the past and current knowledge available on experimental tumor models and human clinical studies targeting TAMs for cancer treatment.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Transformatıon
    ANNUAL REPORT 2012 a time of Transformatıon 238038_Peregrine_Cov.indd 3 8/23/12 8:38 PM Transforming Our Business · Two Phase III-Ready Drug Candidates: Bavituximab and Cotara® · Compelling Bavituximab Proof-of-Concept Clinical Data in Non-Small Cell Lung Cancer · Broad Bavituximab Oncology Program with Multiple Indications Under Clinical Evaluation · Integrated and Growing Commercial Manufacturing Business Transforming Patients’ Lives · Treating Diseases with High Unmet Medical Needs Including NSCLC and GBM · Comprehensive Development Strategy Exploring Broad Potential of Bavituximab in Oncology · Developing New Diagnostics with Potential Applications in Many Life-threatening Diseases · Helping Bring Important New Treatments and Diagnostics to the Market through our Manufacturing Capabilities and Expertise Peregrine’s Advancing Oncology Pipeline PRECLINICAL PHASE I PHASE II PHASE III Bavituximab NSCLC Second-Line NSCLC Front-Line Pancreatic Front-Line Advanced Liver Cancer (HCC) IST Prostate Cancer (CRPC) IST NSCLC Front-Line IST Breast (HER!-Negative) IST Rectal Adenocarcinoma IST PGN!"# PS-Targeted Tumor Imaging Cotara® Recurrent GBM Transforming Our Future With two Phase III-ready programs, an expanding pipeline and a successful commercial manufacturing business, Peregrine is transitioning from an early-stage to a late-stage development company. The company is in a unique position of strength on several fronts with multiple partnering, development and revenue-generating opportunities. These opportunities can help not only transform the company, but potentially the lives of patients with life-threatening diseases. Dear Stockholders, This is a truly transformative time for Peregrine. We are transitioning from an early-stage research organization to a late-stage drug development company, thanks to an expanding product pipeline that now includes two Phase III-ready programs, exceptional proof-of-concept clinical data for our lead product candidate bavituximab and a record-breaking revenue year for our contract manufacturing business.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]